Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study Background: Nontraumatic osteonecrosis of the femoral head (ONFH) is a progressive disease in young adults producing substantial morbidity and frequently resulting in total hip arthroplasty. Although hip-preserving surgical procedures represent the current mainstay of treatment for early disease, medical therapies targeting specific pathways in the ONFH pathogenesis could help prevent disease progression while producing less morbidity. Acetylsalicylic acid (ASA) is a promising alternative to other therapies for ONFH owing to its anti-inflammatory and antithrombotic mechanisms of action and its relatively benign side effect profile.
as chronic autoimmune diseases, acute lymphoblastic leukemia and chronic obstructive pulmonary disease, that require long-term treatment with corticosteroids. In addition to corticosteroids, sickle cell disease and alcohol abuse are also well-documented causes of nontraumatic ONFH. 3, 4 The pathogenesis of ONFH is complex and is often represented by a "multiple hit theory." Specific genetic mutations and abnormalities of the coagulation cascade, angiogenesis and bone formation are coupled with exogenous agents, such as medications, and disease states that interfere with the vascular and endothelial lining of the microvessels within the femoral head. 5, 6 This combination of exogenous insults and an inherent imbalance between thrombotic factors and natural anticoagulants leads to a direct ischemic phenomenon resulting in endothelial injury. 7 Patients with nontraumatic ONFH often have a poor surgical prognosis; therefore, interest is emerging in de veloping medical therapies that target endothelialcoagulation cascade interactions. Owing to limitations of available options, there is currently no consensus regarding effective medical treatment for nontraumatic ONFH at the precollapse stage. Although several theoretically appealing therapies, including bisphosphonates, nonsteroidal anti-inflammatories and a limited weight-bearing protocol, have been clinically evaluated, they have failed to prevent or halt disease progression. 8, 9 Low molecularweight heparin (LMWH) has been shown to delay progression of early ONFH in 1 study; 8 however, concerns regarding the risk of bleeding along with a growing body of evidence regarding heparin-induced osteoporosis and associated fractures, limit the appeal of prolonged LMWH therapy for ONFH prevention. 10, 11 Acetylsalicylic acid (ASA) is an appealing alternative to LMWH for the early treatment of ONFH owing to its fairly benign side effect profile and an impressive range of mechanisms acting upon the known endothelial disease process causing ONFH. Salicylates are some of the most commonly used anti-inflammatory agents. 12 For more than 3 decades, the anti-inflammatory properties of ASA have been almost exclusively attributed to blockade of prostaglandin synthesis via inhibition of cyclooxygenase-1 (COX-1) activity and subsequent inhibition of thromboxane A2. 13 Recent studies have been directed at identifying additional effects of these drugs that could help explain their pharmacologic properties. As such, ASA has been found to inhibit the activation of nuclear factor κ-light-chain-enhancer of activated B cells (NF-kB) without affecting other transcription factors.
14 This finding could help explain the antithrombotic effects of ASA-like drugs on endothelial cells, for instance, the blockade of the expression of COX-2 induced by interleukin (IL)-1, 15 the blunting of the expression of vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in response to tumour-necrosis factor α (TNF-α) and the inhibition of the adhesion of monocytes to endothelial cells. 16 Other effects include a potential enhancing effect on fibrinolytic activity by decreasing plasminogen activator inhibitor-1 (PAI-1) concentration (especially if ASA is administered chronically at low doses), 17 blockade of the activation of the extracellular signal-regulated kinase 18 subgroup of mitogen-activated protein kinases in response to TNF-α 19 and the transcriptional inhibition of endothelial nitric oxide synthase (eNOS). 20 More recently, ASA has also been shown to modulate the vascular endothelium via the eicosanoid lipoxin A4 pathway. 21 Lipoxin A4 is derived from endotheliumproduced arachidonic acid, which binds to polymorphonuclear leukocytes (PMN) and platelets at the location where lipoxins are stored. In addition, ASA has been shown to regulate several pathways involved in vascular hemostasis and, as such, has a vasoprotective effect by inhibiting reactive oxygen species on the endothelium. In addition, ASA regulates the nitric oxide (NO) release pathway, which has indirectly been linked to platelet aggregation and adhesion, 11, 21, 22 and inhibits mammalian target of rapamycin (mTor), 21 a potent regulator of platelet activation and aggregation. 23 Finally, ASA has a role in the structure and function of the fibrin clot (cross-linked fibrin) via a protein acetylation mechanism. [24] [25] [26] Taken together, these findings indicate that the mechanism of action of salicylates in both the inflammatory response and the progression of microthrombotic processes is not straightforward. In addition to its effect on cyclo-oxygenase and eicosanoid metabolism, other mechanisms involving the vascular endothelium contribute to the anti-inflammatory and antithrombotic effects of ASA.
Owing to an expanded understanding of the effects of ASA on the coagulation cascade and the endothelium as well as lack of safe or effective medical alternatives, we designed a study to evaluate the effect of prolonged administration of ASA on the clinical and radiological progression of nontraumatic ONFH.
Methods
In our institution, all patients with suspected ONFH are referred to a dedicated ONFH clinic that has been run by the senior authors (E.J.H. and C.S.) since 2004. All patients presenting with symptomatic precollapse ONFH were consented to daily oral consumption of 81 mg of ASA. The rationale for using ASA was its established antiplatelet and anticoagulant effects as well as its added antiinflammatory benefit.
Patient follow-up took place at the ONFH clinic in either 6-month or 1-year intervals. Radiographs and/or magnetic resonance images (MRIs) were obtained at each follow-up visit, and compliance with ASA was documented.
We compared the study cohort with historical ONFH controls in the literature. The primary outcome was the radiologic progression of ONFH on either radiographs or MRIs. A successful outcome was defined as no difference in ONFH staging, according to the Ficat & Arlet classification, 27 at last patient follow-up compared with initial radiological staging. The secondary outcome was the percentage involvement of the femoral head on radiographs and/or MRI.
Patient selection
We acquired institutional review board approval before data collection. Only patients presenting to our ONFH clinic with nontraumatic precollapse ONFH who consented to receive daily doses of 81 mg ASA were included in our analysis. Patients with traumatic cases of ONFH were excluded as they are inherently variable in terms of the type of trauma sustained, fracture pattern, delay to operative treatment and amount of articular cartilage damage. Conversely, generalized consensus exists regarding the final pathological processes in nontraumatic ONFH as well as its natural history. Therefore, to establish an internally consistent group of patients, we followed only those with nontraumatic ONFH.
Exclusion criteria were history of hip trauma or previous hip surgery, previous use of anticoagulants or bisphosphonates for any reason, noncompliance with ASA treatment and immediate referral for surgical consultation owing to end-stage joint arthritis. It should be noted that evaluation against these criteria as well as radiography and/ or MRI of the affected hip occur in our ONFH clinic for every patient visit. For the patients who fulfilled inclusion criteria, we recorded the following characteristics for analy sis: age, sex and risk factors for ONFH. Although nontraumatic ONFH has been associated with more than 50 medical conditions, 3,4 the 6 most common etiologies were specifically noted: history of corticosteroid use, alcohol use, sickle cell anemia, diabetes mellitus, previous hip trauma and hypercholesterolemia/ hypertriglyceridemia.
We retrieved radiographs and, when available, MRIs for each patient, and we analyzed 2 specific image time points. We retained images taken at initial presentation and either the MRI taken at the most recent follow-up visit or the last MRI before surgical intervention. An independent radiologist blinded to the study purpose reviewed all images. For each time point, we recorded ONFH stage using the Ficat & Arlet 27 classification for radiographs and the Steinberg classification 28 for MRIs. In addition to classification, the percentage of femoral head involvement and location of the ONFH lesion(s) were quantified using previously described methods. 29, 30 We determined interval change in the percentage of femoral head involvement from the most recent MRI. Owing to fundamental similarities in disease classification and variability in MRI or radiograph availability for every patient, as per literature standards, we considered Steinberg stage 0-1 and Ficat & Arlet stage I to be equivalent and Steinberg stage 2 and Ficat & Arlet stage II to be equivalent.
Control group
We compared the treatment group with an established group of historic controls taken from 2 peer-reviewed publications (n = 45) 1,31 that have been used for comparison of ONFH survivorship in at least 1 other study. 8 The publication by Stulberg 
Statistical analysis
We compared nominal and ordinal demographic values using the Pearson c 2 test. Patient demographic characteristics are reported as means with standard deviations. The percent femoral head involvement at first and last study follow-up were recorded as continuous variables and assessed for normality using a Shapiro-Wilk test. We compared femoral head involvement between the groups using a paired Student t test. The presence or absence of radiological progression was recorded as a binary variable. Comparison of progression bewteen the 2 groups was compared using a Fisher exact test. For all statistical tests, we considered results to be significant at p < 0.05.
Results
From 2004 to 2012, 10 patients (6 men, 4 women, 12 painful hips) with nontraumatic ONFH received ASA therapy, met the study criteria and were included in our analysis ( Table 1) . The average patient age in the study group was 52.9 ± 15.3 years, and the average follow-up was 44.4 ± 21.6 (range 18-84) months. Patient age did not significantly differ between the study and control groups (t = 2.253; p = 0.08), but the ASA group demonstrated a trend toward older patients.
In the ASA group, 2 hips were diagnosed as primary ONFH and 10 were secondary. The most frequently identified causes of secondary ONFH were prior use of corticosteroids (5 of 10), sickle cell disease (4 of 10) and elevated alcohol consumption (1 of 10). All patients reported appropriate compliance with their daily oral dose of 81 mg of ASA. Treatment with ASA did not lead to any bleeding episodes or other adverse effects.
At the time of initial diagnosis, all patients taking ASA had Ficat & Arlet/Steinberg stage II disease on imaging with an average area of femoral head involvement of 38% ± 20% (range 20%-90%). With regard to the study's primary outcome, at an average follow-up of 3.7 years, 11 of 12 patients taking ASA experienced a successful outcome, with no progression of ONFH staging on radiographs or MRI. Compared with the control group, patients taking ASA exhibited a significantly decreased rate of radiographic progression (30 of 45 patients, 66.6% rate of progression v. 1 of 12, 8% rate of progression, p = 0.002) despite older age and a longer average follow-up (Fig. 1a) . When matching groups for the presenting ONFH stage (all patients taking ASA presented with Stage 2 ONFH, and 33 of 45 historical controls presented with ONHF stage 0, 1 or 2), patients taking ASA still exhibited a significantly decreased rate of radiographic progression (1 of 12 patients taking ASA v. 24 of 33 controls, p = 0.001; Fig. 1b) .
With regard to femoral head involvement, the average area of involvement within the group decreased over time (34% ± 24%, p = 0.13; Fig. 2 ). The 1 exception in whom femoral involvement increased despite ASA therapy was a 61-year-old man with a history of heavy ethanol use. He continued his high alcohol intake during the course of his treatment. This patient exhibited substantially higher femoral head involvement (90%) on initial index MRI than the other patients in the ASA cohort (pre-ASA mean of 38%) and rapidly progressed to 100% involvement and Steinberg stage 4 disease over the course of 1 year, requiring referral for total hip arthroplasty (Fig. 3) . When excluding this patient from our analysis, the average femoral head ONFH involvement in the remaining patients taking ASA significantly decreased compared with involvement at the initial diagnosis (27.7%, p = 0.045).
discussion
Recent breakthroughs in the understanding of molecular mechanisms involved in ONFH have spurred interest in evaluating pre-existing medical therapies that could theoretically halt and potentially reverse disease progression. Medical therapies as well as nonpharmacological therapies, including modified weight bearing, hyperbaric oxygen and extracorporeal shock wave therapy, have been the subject of multiple investigations, including several prospective studies. 18, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Bisphosphonates have received specific attention owing to their known effect of decreasing osteoclast-mediated bone turnover that theoretically could prevent subchondral bone collapse. A randomized controlled trial assessing 54 hips reported significantly lower rates of disease progression and need for arthroplasty in patients treated with bisphosphonates for 2 months. 34 However, such positive results are offset by a more recent multicentre, double-blind, prospective, controlled study of alendronate versus placebo that showed no statistically ASA = acetylsalicylic acid; F = female; M = male; ONFH = osteonecrosis of the femoral head. *Mean 54.8 ± 11 yr. †Mean 38% ± 20%. ‡Mean 34% ± 24%.
significant difference in the rates of THA, disease progression or quality of life at 2 year follow-up. 35 Statin therapy provides theoretical benefits in decreasing ONFH progression through a reduction in bone marrow adipocyte size that could reduce intraosseous pressure. 48 Unfortunately, clinical studies performed to date have not shown any difference in ONFH progression. 39 One potential explanation for the failure of these medical therapies is that they target the end-effects of ONFH and do not target the underlying insult. Recent evidence points to a vascular hypothesis for the etiology of ONFH, whereby local endothelial dysfunction leads to clot and fatty emboli formation. 7, 49, 50 It is for this reason that we explored the administration of ASA, a known antiplatelet and modulator of the vascular endothelium, to determine if the medication affects the progression of nontraumatic ONFH.
We found that most patients treated with daily ASA tended not to progress in radiological staging of ONFH over a medium-term follow-up. With the exception of 1 patient with near 100% head involvement, patients taking ASA exhibited a significant decline in femoral head involvement on MRI, indicating a reversal in the disease process. The rate of progression in these patients was markedly improved compared with historical controls despite the control group comprising younger patients followed for a shorter amount of time. To our knowledge, our study represents the first clinical examination of ASA therapy for the treatment of ONFH and the first clinical investigation to show a reversal in the ONFH process in the majority of patients receiving medical therapy.
Limitations
We acknowledge several limitations to our study. First, the small number of patients in the cohort limits the potential conclusions on the effect of ASA to only patients who present with a round head (no subchondral step). However, it should be noted that the study's sample size is comparable to that of other pilot studies for preventative therapies, including enoxaparin 8 and hyperbaric oxygen, 43, 44 for ONFH. Second, the use of historical controls for comparison raises concerns for selection bias or equivalence of populations. We attempted to diminish any potential for bias by having minimal selection criteria for patients started on ASA in the clinic and by using historical controls who have been used in other recent investigations when comparing other treatments for ONFH. 1, 8 It would have been impossible to recruit a control group from the population in the ONFH clinic because all patients were started on ASA if possible. Third, we acknowledge that the follow-ups of both study groups are only short-to midterm and that a longer, prospective follow-up period is required to fully understand the effect of ASA on disease progression and whether ASA therapy will lead to a substantial delay to the need for THA. Also, it is not specified within the historical control population if the use of anticoagulants or antiplatelet agents was part of the study's exclusion criteria. However, given the relatively young average age of this population (43 yr), the regular use of these agents to prevent heart disease or stroke is unlikely or could be limited to only a minority of these patients. 
conclusion
Findings from this observational study suggest that ASA administration for patients in early to intermediate stages of nontraumatic ONFH halts radiographic progression and may actually reverse the disease process in the shortterm. Such effects are surmised to arise from ASA's known anticoagulant properties and its positive modulatory and protective action on the vascular endothelium. Although our study was limited by its small sample size, it is important to note that this size is comparable to that in recent literature examining other pharmacological candidates for ONFH treatment. We have used these preliminary findings as a basis to develop a larger, multicentre prospective study to further elucidate the potential benefit of ASA treatment for precollapse ONFH. 
